Semaglutide vs. Tirzepatide: How to Choose

Quick answer: Semaglutide and tirzepatide are both once-weekly injectable medications that often produce significant weight loss by working with your body's own hormone signaling. The core difference is mechanism: semaglutide acts on one hormone pathway (GLP-1), while tirzepatide acts on two (GLP-1 and GIP). In published clinical trials, tirzepatide has generally been associated with somewhat greater average weight loss than semaglutide — but "generally greater on average" doesn't mean "better for you specifically." Individual response varies substantially, and many patients do extremely well on either medication.

Not sure where to start? Check your eligibility for Evergreen Lean. For a broader introduction to how GLP-1 therapy works before diving into this comparison, see our Complete Guide to GLP-1 Weight Loss Treatment.

How They Work: The Mechanism Difference

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut naturally releases after eating, which stimulates insulin release, suppresses glucagon, slows gastric emptying, and increases satiety.

Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP has its own effects on insulin secretion and fat metabolism, and the combination of both pathways appears to produce a stronger overall effect on appetite and blood sugar regulation than either pathway alone. This dual mechanism is the main scientific rationale behind tirzepatide's development and its frequent positioning as an option for patients who haven't seen the results they wanted from semaglutide.

Weight Loss: What the Data Shows

Clinical trial data for semaglutide has shown average weight reductions in the range of 10–15% of body weight over roughly 68 weeks in non-diabetic patients with obesity. Tirzepatide trials have generally reported somewhat higher average weight loss (on average 5% more) over similar timeframes, with some trial arms — particularly at higher doses — showing average reductions exceeding that range.¹

These are population averages from clinical trials, not individual guarantees. Dose, duration of treatment, adherence, diet, activity level, and individual biology all affect real-world results more than the specific medication alone in many cases.

Side Effects: How Do They Compare?

The side-effect profiles of semaglutide and tirzepatide are similar, since both work by slowing digestion and altering appetite signaling. Common side effects for both include:

Neither medication has been shown to have a clearly better or worse overall side-effect burden than the other in a way that applies broadly — patient experience varies. Some patients who struggle with nausea on one medication find the other more tolerable, which is one reason a provider may recommend switching rather than stopping treatment altogether.

Managing nausea on either medication? Read our full guide to managing GLP-1 nausea.

Dosing and Administration

Both medications are administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm, with injection sites rotated to avoid skin reactions. Both use a gradual dose-escalation schedule over several weeks to months, designed to minimize gastrointestinal side effects as your body adjusts. Neither requires daily dosing, and both require refrigerated storage.

Who Tends to Do Well on Each

There's no universal rule for which medication is "better" — but a few patterns are worth knowing:

• Patients newer to GLP-1 therapy often start with semaglutide, given its longer track record and extensive real-world data.
• Patients who've plateaued or seen limited results on semaglutide are frequently good candidates for tirzepatide, given its dual mechanism.
• Patients highly sensitive to gastrointestinal side effects may do better on whichever medication they tolerate best — which sometimes isn't predictable in advance and may require trying one before switching to the other.
• Patients with type 2 diabetes may have additional considerations based on their glucose control needs, which your provider will factor into the recommendation.

How Evergreen Lean Approaches This Decision

Rather than defaulting every patient to one medication, Evergreen Lean's providers evaluate your health history, prior treatment experience (if any), and goals to recommend semaglutide or tirzepatide specifically for you — and can help you transition between the two if your current treatment isn't producing the results you expected.

Learn more about the program on our Evergreen Lean page.

Frequently Asked Questions

Is tirzepatide simply a "stronger" version of semaglutide?

Not exactly — it works through an additional hormone pathway rather than a higher dose of the same mechanism. That said, trial data does generally show somewhat greater average weight loss with tirzepatide.

Can I switch from semaglutide to tirzepatide if it's not working for me?

Yes, this is a common and reasonable conversation to have with your provider if you've plateaued or aren't tolerating your current medication well. It is important to note if you do switch, you will have to start the titration from the beginning.

Is one medication safer than the other?

Both have similar, well-documented side-effect profiles. Neither is considered inherently "safer" in a way that applies to every patient — your provider will consider your specific health history.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36.

Medically reviewed by Dr. Casey Greene, PharmD, IFMCP, Peptide Subject Matter Expert, Evergreen Telehealth, on September 4, 2026.

This article is for general educational purposes and is not a substitute for individualized medical advice. Only a licensed healthcare provider can determine which medication and dose is appropriate for you.

Information and statements on this material have not been evaluated by the Food and Drug Administration. Evergreen Telehealth content is for general education and should never replace professional medical advice that considers your individual health.